Tromsoe

• rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting
  2024-516078-31-00 10 2015-05-05 Recurrent and Primary Refractory Ewing Sarcoma
• NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years Recruiting
  2024-518254-16-00 5 2013-03-01 Acute Myeloid Leukemia (Pediatric 0-18 years)
• Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended recruitment
  2024-510730-40-00 5 2024-12-12 Hidradenitis Suppurativa
• PErsonalized TREatment of high-risk MAmmary Cancer - the PETREMAC trial Ended recruitment
  2024-519364-40-00 4 2024-11-29 Breast cancer
• The p53 breast cancer trial Ended recruitment
  2024-515135-29-00 4 2024-10-12 breast cancer
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study inves … Ended recruitment
  2022-502640-12-01 9 2024-09-27 Non-small cell lung cancer (NSCLC)
• RElapse from Mrd Negativity As iNdication for Treatment Ended recruitment
  2023-510215-18-00 10 2024-09-26 Multiple myeloma
• Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcuta … Ended recruitment
  2023-510184-35-00 6 2024-08-20 Rheumatoid arthritis
• Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotacti … Ended recruitment
  2024-512439-54-01 4 2024-07-24 Non-small cell lung cancer (NSCLC)
• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2022-502238-22-00 5 2024-05-14 Ulcerative Colitis
• A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati … Ended recruitment
  2023-504124-26-00 5 2024-04-04 Chronic Kidney Disease and High Proteinuria
• A Study of Mirikizumab (LY3074828) in Pediatric Participants with Crohn’s Disease (AMAY) Ended recruitment
  2024-511472-32-00 5 2024-03-12 Crohn's Disease
• MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended recruitment
  2023-504816-14-00 5 2024-03-08 Endometrial cancer
• Effects of BBP-418 (ribitol) in Patients with LGMD2I Ended recruitment
  2023-503379-33-01 5 2024-02-12 Limb Girdle Muscular Dystrophy 2I/R9
• Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841) Ended recruitment
  2022-500100-21-01 4 2023-09-11 Follicular lymphoma
• LOGGIC/FIREFLY-2: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy Ended recruitment
  2024-510742-13-00 5 2023-04-19 Pediatric low-grade glioma harboring an activating RAF alteration requ
• A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years o … Ended recruitment
  2023-504277-20-00 5 2023-01-30 Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorde
• A double-blind randomized placebo-controlled four-arm trial to assess the efficacy of oral bicarbonate and intravenous butylscopolamine brom … Ended recruitment
  2024-511848-55-00 5 2023-01-03 childbirth
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504741-32-00 4 2022-11-30 Moderately to Severely Active Crohn's Disease
• METIMMOX-2: Oxaliplatin Chemotherapy and Immunotherapy to Patients with the Common pMMR/MSS Type of Large Bowel Cancer Spread to Other Organ … Ended recruitment
  2022-500027-76-00 4 2022-10-05 Colorectal cancer
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Ended recruitment
  2023-506177-35-00 11 2021-10-23 Ovarian, fallopian tube, or primary peritoneal carcinoma.
• Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera … Ended recruitment
  2022-501973-37-00 5 2020-01-30 Endometrial cancer

Showing 73–96 of 124 trials